TICKERNERD
Menu
NXTCNXTCHealthcare · Biotechnology

NXTC Stock Forecast: NextCure, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$6.29
+0.64% on the day

The 2 Wall Street analysts covering NextCure, Inc. hold a median 12-month price target of $23 — +257.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$28.8M
Ticker Nerd rank
76 / 100
Median analyst target
$23
Analysts covering
2
Total return, dividends reinvested
1W
−23.4%
1M
+23.1%
YTD
−55.7%
1Y
+23.1%
From 52W high
−55.9%
From 52W low
+293.1%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NXTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NextCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
76 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Growth
86
Accruals
84
Revisions
83
Momentum
57
Issuance
57
Quality
26
Volatility
24
Value
22

Size (86): Smaller than most of the companies we track.

Value (22): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NXTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26NXTCHigh $25Median $23Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $20Median $23High $25

The green dot is the last close — the median target sits +257.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026LUCID CAPITAL MARKETSInitiatesBuy$25
7 Nov 2025Ladenburg ThalmannUpgradeBuy—
15 July 2025Piper SandlerMaintainsOverweight—
1 July 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.MaintainsBuy—
2 Aug 2024NeedhamReiteratesBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024NeedhamReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
20 Mar 2024NeedhamMaintainsBuy—
14 Dec 2023NeedhamMaintainsBuy—
8 Aug 2023HC Wainwright & Co.InitiatesBuy—
4 Aug 2023NeedhamReiteratesBuy—
5 May 2023NeedhamReiteratesBuy—
3 Mar 2023NeedhamReiteratesBuy—
4 Nov 2022Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXTC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NXTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

NextCure, Inc. (NXTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 45% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−204.6%

Higher than 7% of US stocks

Return on assets
−69.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NXTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NXTCNextCure, Inc.$28.8M
76
ACTUActuate Therapeutics, Inc.$29.1M
27
BYSIBeyondSpring, Inc.$29.6M
21
LTRNLantern Pharma, Inc.$29.9M
56
DYAIDyadic International, Inc.$27.6M
19
KYNBKyntra Bio, Inc.$30.4M
44
QNTMQuantum BioPharma Ltd.$27.0M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NextCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXTC news & analysis

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

PRNewsWire · 10 Aug 2026positive

Avere Therapeutics announced a $500 million private placement from leading healthcare investors, in addition to a previously announced $320 million concurrent private investment. The combined proceeds are expected to fully fund Avere's operating plan into 2029 and support development of its lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Why it matters — This financing strengthens the combined company's balance sheet to accelerate development of AVR-001, a development program relevant to NXTC watchers following the entity.

FAQ

Frequently asked questions about NXTC stock

What is the NXTC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NextCure, Inc. have a median 12-month price target of $23, with estimates ranging from $20 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NXTC stock a buy right now?

Of the 2 analysts covering NextCure, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NextCure, Inc. 76 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NXTC?

As at 22 Aug 2026, NextCure, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will NXTC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +257.7% from the last close, and Ticker Nerd's factor model ranks NextCure, Inc. 76 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NXTC stock forecast for 2030?

No analyst covering NextCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $25 over the next 12 months.

How has NXTC stock performed over the past year?

NextCure, Inc. returned +23.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NextCure, Inc. do?

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and other immune-related diseases.

What is the latest news on NXTC?

The most recent item we track (PRNewsWire, 10 Aug 2026): "Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001". Avere Therapeutics announced a $500 million private placement from leading healthcare investors, in addition to a previously announced $320 million concurrent private investment. The combined proceeds are expected to fully fund Avere's operating plan into 2029 and support development of its lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Company

About NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and other immune-related diseases. Headquartered in Beltsville, Maryland, the company concentrates on therapies designed to restore normal immune function rather than broadly suppress or stimulate the immune system. NextCure’s pipeline includes product candidates such as NC410, a fusion protein targeting the LAIR pathway being evaluated in combination with established oncology treatments, and LNCB74, an antibody-drug conjugate directed at the B7-H4 cancer target. The company also advances additional clinical and preclinical programs addressing both oncology and non-oncology indications, including chronic bone diseases and neurodegenerative conditions. Operating within the biotechnology segment of the healthcare sector, NextCure collaborates selectively with partners to progress certain programs, while leveraging its discovery capabilities to identify new immunomodulatory targets. Its activities contribute to the broader immuno-oncology and immune-disease treatment landscape by aiming to provide differentiated, mechanism-based therapeutic options for patients with significant unmet medical needs.

CEO Mr. Michael S. Richman MSBA · 40 employees · United States · https://www.nextcure.com